Nesiritidacetat CAS:114471-18-0

Nesiritide (Natrecor) is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation.

Neseritide was believed initially to be beneficial for acute decompensated congestive heart failure. It received approval from the United States' Food and Drug Administration for this purpose in 2001 after initial non-approval. In July 2011 the results of the largest study so far for nesiritide was published in The New England Journal of Medicine; it showed that nesiritide was not associated with a change in mortality or re-hospitalizations.

Mainly has a strong angiotensin II vasoconstriction and increase in blood pressure. The mechanism is: 1. So that the body arteriole smooth muscle contraction, increased peripheral resistance; 2. So increase the release of adrenal aldosterone, causing sodium retention, increased blood volume; 3. Directly contribute to renal tubular sodium and water reabsorption; 4. So the brain central nervous sympathetic vasoconstrictor activity, causing increased peripheral vascular resistance; 5. Stimulate the adrenal medulla to release epinephrine and norepinephrine.